Learn About Agranulocytosis

What is the definition of Agranulocytosis?

White blood cells fight infections from bacteria, viruses, fungi, and other germs. One important type of white blood cell is the granulocyte, which is made in the bone marrow and travels in the blood throughout the body. Granulocytes sense infections, gather at sites of infection, and destroy the germs.

When the body has too few granulocytes, the condition is called agranulocytosis. This makes it harder for the body to fight off germs. As a result, the person is more likely to get sick from infections.

Save information for later
Sign Up
What are the alternative names for Agranulocytosis?

Granulocytopenia; Granulopenia

What are the causes of Agranulocytosis?

Agranulocytosis may be caused by:

  • Autoimmune disorders
  • Bone marrow diseases, such as myelodysplasia or large granular lymphocyte (LGL) leukemia
  • Certain medicines used to treat diseases, including cancer
  • Certain street drugs
  • Poor nutrition
  • Preparation for bone marrow transplant
  • Problem with genes
What are the symptoms of Agranulocytosis?

Symptoms of this condition may include:

  • Fever
  • Chills
  • Malaise
  • General weakness
  • Sore throat
  • Mouth and throat ulcers
  • Bone pain
  • Pneumonia
  • Shock
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Agranulocytosis?

Treatment depends on the cause of the low white blood cell count. For example, if a medicine is the cause, stopping or changing to another medicine may help. In other cases, medicines to help the body make more white blood cells will be used.

Who are the top Agranulocytosis Local Doctors?
DD
Dr. David C. Dale
Hematology Oncology
Elite
Highly rated in
11
conditions
Hematology Oncology

UW Medicine

General Internal Medicine Center At UWMC-Roosevelt

4245 Roosevelt Way Ne, 
Seattle, WA 

David Dale is a Hematologist Oncology expert in Seattle, Washington. Dale has been practicing medicine for over 57 years and is rated as an Elite expert by MediFind in the treatment of Agranulocytosis. He is also highly rated in 11 other conditions, according to our data. His top areas of expertise are Agranulocytosis, Chronic Familial Neutropenia, Cyclic Neutropenia, Infantile Neutropenia, and Bone Marrow Transplant. Dale is currently accepting new patients.

GL
Gary H. Lyman
Dr. Gary H. Lyman
Oncology | Hematology Oncology
Elite
Highly rated in
10
conditions
Oncology
Hematology Oncology

Seattle Cancer Care Alliance At South Lake Union

825 Eastlake Ave E, 
Seattle, WA 

Gary Lyman is an Oncologist and a Hematologist Oncology expert in Seattle, Washington. Lyman has been practicing medicine for over 51 years and is rated as an Elite expert by MediFind in the treatment of Agranulocytosis. He is also highly rated in 10 other conditions, according to our data. His top areas of expertise are Febrile Neutropenia, Agranulocytosis, Venous Thromboembolism (VTE), and Breast Cancer. Lyman is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn more
JS
Julia Skokowa
Elite
Highly rated in
8
conditions

University Of Tübingen

Tuebingen, BW, DE 

Julia Skokowa practices in Tuebingen, Germany. Skokowa is rated as an Elite expert by MediFind in the treatment of Agranulocytosis. She is also highly rated in 8 other conditions, according to our data. Her top areas of expertise are Agranulocytosis, Cyclic Neutropenia, Severe Congenital Neutropenia, and Chronic Familial Neutropenia.

View All Doctors
What is the outlook (prognosis) for Agranulocytosis?

Treating or removing the cause often results in a good outcome.

How do I prevent Agranulocytosis?

If you are having treatment or taking medicine that could cause agranulocytosis, your health care provider will use blood tests to monitor you.

Blood cells
What are the latest Agranulocytosis Clinical Trials?
A Phase I Study of MozobilTM in the Treatment of Patients With WHIMS
Who is this study for: Patients with WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome)
Enrollment Status: Recruiting
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drug: Mozobil
Study Phase: Phase 1/Phase 2

Background: WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is caused by various genetic changes that increase the activity of the chemokine receptor, CXCR4. Excessive function of this receptor causes mature neutrophils (part of the white blood cells) to be retained within the bone marrow rather than being released to the blood and is one of the causes of severe inherited neutrope...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Evaluation of Risk Factors Associated With Myelosuppression (Grade 4 Neutropenia) in Breast Cancer Patients Treated With Palbociclib in the Post-marketing Setting: Nested Case-control Study Using the Medical Information Database Network (MID-NET) Database
Enrollment Status: Not yet recruiting
Publish Date: February 02, 2023

Summary: The purpose of this study is to explore risk factors for grade 4 neutropenia in users of the study medicine Palbociclib for the potential treatment of Palbociclib. This study is seeking participants: treated with the study medicine Palbociclib having any breast cancer records in same month as the initiation date having prescription records of palbociclib from 15 December 2017 to 29 February 2024 T...

View All Clinical Trials
What are the Latest Advances for Agranulocytosis?
Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
Condition: Locally Advanced Esophageal Carcinoma (LA-ESCC)
Journal: Radiation oncology (London, England)
Treatment Used: Chemotherapy with Carboplatin (TC)
Number of Patients: 201
Published: December 30, 2022
A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma.
Condition: Elderly Patients with Advanced-Stage, Aggressive Non-Hodgkin Lymphoma (NHL)
Journal: Journal of clinical and experimental hematopathology : JCEH
Treatment Used: Pirarubicin and Modified CHOP Regimen (THP-COP)
Published: December 27, 2022
Tired of the same old research?
Check Latest Advances
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Condition: HER2-Positive Breast Cancer
Journal: BMC medicine
Treatment Used: Neoadjuvant Pyrotinib, Trastuzumab, and Docetaxel
Number of Patients: 355
Published: December 27, 2022
View All Latest Advances
Who are the sources who wrote this article ?

Published Date: April 29, 2022
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Cook JR. Bone marrow failure syndromes. In: Hsi ED, ed. Hematopathology. 3rd ed. Philadelphia, PA: Elsevier; 2018:chap 5.

Klokkevold PR, Mealey BL. Influence of systemic conditions. In: Newman MG, Takei HH, Klokkevold PR, Carranza FA, eds. Newman and Carranza's Clinical Periodontology. 13th ed. Philadelphia, PA: Elsevier; 2019:chap 14.

Sive J, Foggo V. Haematological disease. In: Feather A, Randall D, Waterhouse M, eds. Kumar and Clarke's Clinical Medicine. 10th ed. Philadelphia, PA: Elsevier; 2021:chap 17.